KORU Medical Systems, Inc.(KRMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,155 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
KRMD Stock Analysis & AI Quality Score
AI stock analysis and institutional research for KORU Medical Systems, Inc. (KRMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRMD at 35.2/100 on a 32-signal composite quality model, placing it at rank #2,155 of 2,879 stocks — the bottom half of the AI-ranked universe. KRMD scores in the top quartile across revenue growth (80.3). Areas of concern include revenue scale (9.7) and balance sheet strength (17.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), KORU Medical Systems, Inc. reports quarterly revenue of $11.8M, net income of $-807.1K, an operating margin of -7.3%. Top institutional holders of KRMD by reported 13-F value include First Light Asset Management,, Topline Capital Management,, BlackRock,, based on the most recent SEC filings. KRMD trades on the Nasdaq exchange and files with the SEC under CIK 704440. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KORU Medical Systems, Inc. directly from SEC EDGAR. KORU Medical Systems, Inc.'s 13F Pro composite quality score has ranged between 14 and 35 since 2023, currently 35.2 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.
Revenue
Q1 2026
$11.8M
Net Income
Q1 2026
$-807.1K
Free Cash Flow
Q1 2026
$-31.5K
Operating Margin
Q1 2026
-7.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+22.2% YoYNet Income
+56.5% YoYOperating Income
+53.9% YoYEPS (Diluted)
+53.8% YoYTotal Assets
+3.6% YoYOp. Cash Flow
+244.6% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $41.1M +22.2% | $33.6M +20.6% | $27.9M +18.8% | $23.5M -2.8% | $24.2M +4.4% | $23.2M |
| Net Income | $-2.6M +56.5% | $-6.1M +30.0% | $-8.7M -89.8% | $-4.6M -276.5% | $-1.2M -314.8% | $564.3K |
| Operating Income | $-3.0M +53.9% | $-6.4M +40.2% | $-10.8M -53.4% | $-7.0M -460.2% | $-1.3M -314.2% | $585.7K |
| EPS (Diluted) | $-0.06 +53.8% | $-0.13 +31.6% | $-0.19 -90.0% | $-0.10 -233.3% | $-0.03 -400.0% | $0.01 |
| Total Assets | $28.2M +3.6% | $27.2M -35.7% | $42.3M +2.5% | $41.3M +3.4% | $39.9M +187.6% | $13.9M |
| Operating Cash Flow | $462.4K +244.6% | $-319.7K +94.1% | $-5.4M -25.1% | $-4.3M -481.1% | $-743.3K -331.8% | $320.6K |
AI Insight: KRMD Financial Trends
KORU Medical's revenue has grown 50% from $8M in Q2 2024 to $12M in Q1 2026, but the company remains persistently unprofitable with no debt data available.
• Revenue grew steadily from $8M in Q2 2024 to $12M in Q1 2026, a 50% increase over six quarters.
• Operating losses narrowed from -$2M in Q3–Q4 2024 to -$1M or near breakeven in Q2–Q4 2025, signaling improving cost leverage.
• Equity has held relatively stable between $16M–$19M across all eight quarters, suggesting losses are being absorbed without major dilution.
⚠ Operating cash flow has oscillated between -$1M and +$1M; sustained positive FCF generation remains unproven despite revenue growth.
⚠ Net income returned to -$1M in Q1 2026 after near-breakeven in Q4 2025 — profitability inflection remains elusive.
⚠ Debt data is absent across all periods; hidden leverage or future financing needs cannot be assessed.
AI Insight: KRMD Ratio Trends
KORU Medical's operating losses have narrowed sharply from a -20.8% trough in Q3 2024 to single digits, but profitability remains elusive across all metrics.
• Operating margin improved dramatically from -20.8% in Q3 2024 to -3.1% in Q2 2025, signaling meaningful cost discipline or revenue scaling.
• Operating margin has rewidened to -7.3% in Q1 2026 from the -3.1% Q2 2025 low, suggesting the improvement is not yet sustained.
• ROIC remains deeply negative at -20.4% in Q1 2026, though well off the -38.4% trough recorded in Q3 2024.
• TTM operating margin of -6.0% and NPM of -5.3% reflect the full-year trend sitting closer to recent improvements than to the 2024 lows.
⚠ Operating margin slipped from -3.1% in Q2 2025 back to -7.3% in Q1 2026 — watch whether Q2 2025 was a one-off inflection or a genuine floor.
⚠ ROE deteriorated to -19.1% in Q1 2026 from -11.4% in Q4 2025 — quarterly rewidening warrants scrutiny of seasonal vs. structural drivers.
⚠ D/E data is unavailable across all periods; balance sheet leverage remains unquantifiable, a key gap for credit risk assessment.
Get alerted when KRMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for KORU Medical Systems, Inc. including:
Top Institutional Holders of KRMD
First Light Asset Management, LLC
$16.3M3,768,380 shTopline Capital Management, LLC
$15.2M3,514,911 shBlackRock, Inc.
$10.2M2,371,826 shVANGUARD CAPITAL MANAGEMENT LLC
$7.3M1,686,224 shGEODE CAPITAL MANAGEMENT, LLC
$4.5M1,051,208 shSimcoe Capital LLC
$3.5M811,247 shMeros Investment Management, LP
$3.3M760,451 shEmpire Financial Management Company, LLC
$3.0M703,139 shSTATE STREET CORP
$2.8M649,229 shArchon Capital Management LLC
$2.8M642,923 sh
| Fund | Value | Shares |
|---|---|---|
| First Light Asset Management, LLC | $16.3M | 3,768,380 |
| Topline Capital Management, LLC | $15.2M | 3,514,911 |
| BlackRock, Inc. | $10.2M | 2,371,826 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.3M | 1,686,224 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.5M | 1,051,208 |
| Simcoe Capital LLC | $3.5M | 811,247 |
| Meros Investment Management, LP | $3.3M | 760,451 |
| Empire Financial Management Company, LLC | $3.0M | 703,139 |
| STATE STREET CORP | $2.8M | 649,229 |
| Archon Capital Management LLC | $2.8M | 642,923 |
More Healthcare Companies
View all Healthcare →Put KRMD on your watchlist
Track score changes the day KORU Medical Systems, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KRMD a good stock to buy?
13F Pro's AI-powered analysis of KORU Medical Systems, Inc. (KRMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KRMD are available on the KRMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own KRMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KRMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KORU Medical Systems, Inc.'s investment landscape.